跳转至内容
Merck
CN
  • Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines.

Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines.

Alcoholism, clinical and experimental research (2014-11-26)
Vikrant Rachakonda, Charles Gabbert, Amit Raina, Huanan Li, Shahid Malik, James P DeLany, Jaideep Behari
摘要

Dysregulated adipose tissue metabolism has been implicated in the pathogenesis of alcoholic liver disease in murine models. We aimed to characterize serum markers of adipose tissue metabolism and inflammation in patients with severe acute alcoholic hepatitis (AAH) and determine their utility to predict survival in severe AAH. A prospective, case-control study design was used. Seventy-six patients hospitalized with severe AAH and 25 ambulatory patients with alcoholic cirrhosis as controls were included. Serum samples were collected for biochemical analyses. Patients were followed for 180 days after enrollment to determine the survival. AAH patients exhibited higher serum glycerol and free fatty acid levels, suggesting enhanced adipose tissue triglyceride hydrolysis. Patients with AAH demonstrated a distinct serum lipidomic profile compared with alcoholic cirrhosis but not in systemic and adipose-specific insulin resistance. AAH patients had higher serum resistin and plasmin activation inhibitor-1 levels, while serum leptin was decreased. Serum levels of the prolipolytic cytokines tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, and IL-15 were significantly higher in AAH patients. Only 53% of AAH patients survived 180 days after admission, while all cirrhotic patients were alive at the end of the study period. Among patients with severe AAH, white blood cell count, hemoglobin, resistin, IL-6 and TNF-α were associated with 180-day survival, and all 5 markers demonstrated accuracy by area under receiver-operator curve analysis. Serum IL-6 levels ≥38.66 pg/ml most precisely identified deaths in severe AAH. Patients with IL-6 ≥ 38.66 pg/ml had significantly decreased mean survival compared to those with lower levels. AAH patients demonstrate evidence of increased adipose tissue lipolysis and altered serum lipidomic profile compared with alcoholic cirrhosis patients. IL-6 may be a useful biomarker to risk stratify severe AAH patients at the highest risk of mortality.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甘油, ACS reagent, ≥99.5%
Sigma-Aldrich
庚烷, suitable for HPLC, ≥99%
Sigma-Aldrich
甘油, Molecular Biology, ≥99.0%
Sigma-Aldrich
甘油, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
庚烷, ReagentPlus®, 99%
Sigma-Aldrich
甘油, ≥99.5%
Sigma-Aldrich
庚烷, HPLC Plus, for HPLC, GC, and residue analysis, 99%
Sigma-Aldrich
庚烷, puriss. p.a., reag. Ph. Eur., ≥99% n-heptane basis (GC)
Sigma-Aldrich
甘油 溶液, 83.5-89.5% (T)
Sigma-Aldrich
甘油, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
甘油, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Supelco
甘油, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
胆红素, ≥98% (EmM/453 = 60), powder
Sigma-Aldrich
甘油, BioXtra, ≥99% (GC)
Sigma-Aldrich
肌酸酐, anhydrous, ≥98%
USP
甘油, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
庚烷, anhydrous, 99%
Sigma-Aldrich
甘油, puriss., anhydrous, 99.0-101.0% (alkalimetric)
Sigma-Aldrich
甘油, FCC, FG
Sigma-Aldrich
甘油, puriss. p.a., ACS reagent, anhydrous, dist., ≥99.5% (GC)
Sigma-Aldrich
甘油, meets USP testing specifications
Sigma-Aldrich
甘油 溶液, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
庚烷, suitable for HPLC, ≥96%
Supelco
甘油, analytical standard
Sigma-Aldrich
胆红素, purum, ≥95.0% (UV)
Supelco
庚烷, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
庚烷, analytical standard
Supelco
肌酐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甘油, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
庚烷, biotech. grade, ≥99%